Yeni tanı demir eksikliği anemisi olan hastalarda bazal immatür retikulosit fraksiyonu (IRF) düzeyi ve demir tedavisine IRF yanıtının değerlendirilmesi

Year 2018, Volume: 10 Issue: 4, 431 - 435, 01.12.2018

Mustafa Kaplan Nisbet Yılmaz Gülsüm Özet

https://doi.org/10.21601/ortadogutipdergisi.474070

Abstract

Amaç: Bu çalışmada immatür retikulosit fraksiyonu (IRF)’nun sağlıklı populasyondaki bazal değerini, demir eksikliği anemisi (DEA) olan hastalarda bazal IRF düzeyini ve oral demir replasman tedavisine IRF yanıtının değerlendirilmesini amaçladık.
Gereç ve Yöntem: Bu çalışma Mart 2011-Eylül 2011 tarihleri arasında dahiliye polikliniğine başvuran ve yeni tanı DEA tanısı konulan 100 çalışma hastası ve 103 sağlıklı kontrol grubu ile yapılmıştır. Hastalardan tanı anında tam kan sayımı, retikulosit, IRF parametreleri çalışıldıktan sonra çalışma grubu hastalarına oral demir replasman tedavisi başlanmıştır. 7 gün sonra kontrole çağrılan hastalarda aynı parametreler prospektif olarak tekrar çalışılmıştır. Çalışma için Beckman-Coulter LH750/780 cihazı kullanılmıştır.
Sonuçlar: Kontrol grubu ve çalışma grubununun cinsiyet dağılımı benzer olup çalışmaya katılanların ortalama yaşı 44’tü. Çalışma grubunda hastaların tedavi öncesi ortalama IRF değeri kontrol grubundaki hastalara göre düşük bulunmuştur (%0.22±0.05 / %0.24±0.05; p>0.05). 7 günlük tedavi sonrası kontrole çağrılan hastalarda hemoglobin değeri 9.75 ±1.52 g/dl’den 10.8±1.48 g/dl’ ye (p<0.05), IRF değerleri ise %0.22±0.05’ten %0.43±0.39’a yükselmiştir (p<0.05). Alt grup analizlerinde hemoglobin değeri düşük olanlarda, 45 yaşından genç olanlarda ve kadın cinsiyette IRF artışı daha belirgin olmakla beraber istatistiksel olarak anlamlı farklılık bulunmamıştır (p>0.05).
Sonuç: Bu çalışmada sağlıklı populasyonda Beckman-Coulter LH750/780 cihazı ile ölçülen bazal IRF değeri %0.24±0.05 olarak bulunmuştur. Yeni tanı DEA olan hastalarda IRF düzeyinin düştüğü ve oral demir replasman tedavisi alan hastalarda IRF’nin retikulosit krizine korele bir şekilde arttığı gösterilmiştir. 

Keywords

İmmatür retikulosit fraksiyonu, retikulosit, mikrositik anemi

Evaluation of basal immature reticulocyte fraction (IRF) level and IRF response to iron therapy in patients with newly diagnosed iron deficiency anemia

Abstract

Aim: In this study, we aimed to evaluate the basal value of immature reticulocyte fraction (IRF) in healthy population, the baseline IRF level in patients with iron deficiency anemia (IDA), and the IRF response to oral iron replacement therapy.
Material and Method: This study was conducted with 100 study patients diagnosed with IDA and 103 control group patients who were admitted to the internal medicine polyclinic between March 2011 and September 2011. At the time of diagnosis whole blood count, reticulocyte and IRF parameters were studied and then oral iron replacement therapy was started to the study group patients. The same parameters were prospectively restudied after 7 days of follow-up. Beckman-Coulter LH750 / 780 instrument was used for the study.
Results: The gender distribution of the control and study group was similar and the average age of the participants was 44. In the study group, the mean pre-treatment IRF value of the patients was found to be lower than the mean IRF value of the control group (0.22 ± 0.05% / 0.24% ± 0.05%; p> 0.05). In patients who were referred for control in the seventh day of treatment, the mean hemoglobin value increased from 9.85 ± 1.52 g / dL to 10.8 ± 1.48 g / dL (p <0.05) and IRF values increased from 0.22 ± 0.05% to 0.43 ± 0.39% (p <0.05). Although the IRF increase was more obvious in patients with low hemoglobin levels, younger age and female sex in subgroup analysis, there was no statistically significant difference between groups.
Conclusion: In this study, baseline IRF value of healthy population measured with Beckman-Coulter LH750 / 780 instrument was found 0.24 ± 0.05%. IRF levels decrease in patients with newly diagnosed IDA and increases in correlation with the reticulocyte crisis after oral iron replacement therapy

Keywords

Immature reticulocyte fraction, reticulocyte, microcytic anemia

References

• 1. Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA 1997; 277: 973.
• 2. Price EA, Mehra R, Holmes TH, Schrier SL. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis 2011; 46: 159.
• 3. Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int J Clin Lab Res 1998; 28: 1.
• 4. Rowan RM, Cavill I, Corberand JX. The reticulocyte count: progress towards the resurrection of a useful clinical test. Clin Lab Haematol 1996; 18 Suppl 1: 3.
• 5. Davis BH, Bigelow NC. Automated reticulocyte analysis. Clinical practice and associated new parameters. Hematol Oncol Clin North Am 1994; 8: 617.
• 6. Morkis IV, Farias MG, Scotti L. Determination of reference ranges for immature platelet and reticulocyte fractions andreticulocyte hemoglobin equivalent. Rev Bras Hematol Hemoter. 2016 Oct Dec; 38: 310-3.
• 7. Chang CC, Kass L. Clinical significance of immature reticulocyte fraction determined by automated reticulocyte counting. Am J Clin Pathol 1997; 108: 69.
• 8. George P, Wyre RM, Bruty SJ, et al. Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma. J Hematother Stem Cell Res 2000; 9: 219.
• 9. Grotto HZ, Vigoritto AC, Noronha JF, Lima GA. Immature reticulocyte fraction as a criterion for marrow engraftment. Evaluation of a semi-automated reticulocyte counting method. Clin Lab Haematol 1999; 21: 285.
• 10. Buttarello M, Temporin V, Ceravolo R, Farina G, Bulian P. The new reticulocyte parameter (Ret-y) of the Sysmex XE 2100. Its use in the diagnosis and monitoring of posttreatment sideropenic anemia. Am J Clin Pathol 2004;121: 489–95.
• 11. Buttarello M, Bulian P, Farina G, Petris MG, Temporin V, Toffolo L. Five fully automated methods for performing immature reticulocyte fraction. Comparison in diagnosis of bone marrow aplasia. Am J Clin Pathol 2002; 117: 871–9.
• 12. Piva E, Brugnara C, Chiandetti L, Plebani M. Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis. Clin Chem Lab Med 2010; 48: 1369–80.
• 13. Takeuchi K, Kawai Y, Watanabe K. (The measurement of immature reticulocyte fractions and clinical significance).Rinsho Byori. 2001 May; 49: 480-4.
• 14. Tsuda I, Tatsumi N. Maturity of reticulocytes in various hematological disorders. Eur J Haematol 1989; 43: 252–4.
• 15. Torres Gomez A, Casano J, Sanchez J, Madrigal E, Blanco F, Alvarez MA. Utility of reticulocyte maturation parameters in the differential diagnosis of macrocytic anemia. Clin Lab Haematol 2003; 25: 283–8.
• 16. Nazarenko GI, Kolenkin SM, Lugovskaia SA, Mikolauskas VP. Significance of parameters of automated reticulocyte analysis in diagnosis and evaluation of treatment outcome in B12-deficient anemia. Clin Lab Diagn 2004 May; 5: 42-5.
• lin Lab Diagn. 2004 May;(5):42-5